@article {Rodr{\'\i}guez-Martin{\'o}2021.09.11.21263211, author = {Esteban Rodr{\'\i}guez-Martin{\'o} and Rafael Medina-Prieto and Jorge Santana-Bagur and Mar{\'\i}a Sant{\'e} and Petraleigh Pantoja and Ana M. Espino and Carlos A. Sariol and Esther A. Torres}, title = {Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators}, elocation-id = {2021.09.11.21263211}, year = {2021}, doi = {10.1101/2021.09.11.21263211}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Patients with immune conditions and immune-modifying therapies were excluded from the Covid-19 vaccine trials. Studies have shown conflicting response to different vaccines in persons receiving immune suppressors or biologics. The aim of this study is to evaluate humoral and cellular response to Covid-19 vaccines in patients with Inflammatory Bowel Disease (IBD) using biologic and/or immunomodulatory (IMM) therapies.Methods Participants are adults with IBD receiving biologics or IMM planning to receive a Covid 19 vaccine. Cellular immunity (CD4+ and CD8+ T cell levels) with flow cytometry are measured at baseline and 2 weeks after each vaccine dose. Humoral immunity (antibody titers and neutralizing capacity,VNT\%) is analyzed by ELISA at baseline, 2 weeks after each dose, and 6 and 12 months after vaccine. We present the early results of the first 19 subjects. The study is approved by the IRB.Results 19 subjects (18 in biologics and 1 in IMM) who received 2 doses of the Pfizer-BioNTech vaccine are included. Total IgG antibodies increased 21.13 times after the first dose and 90 times after the second dose. VTN\% increased 11.92 times after the first dose and 53.79 times after the second dose. When compared with a healthy control cohort, total IgG antibodies and VTN\% were lower in the subjects after the first dose. After the second dose, IgG antibodies increased but remained lower than controls, but VTN\% were similar to controls. CD4 and CD8 mean levels had an upward trend after vaccination.Conclusions Neutralizing capacity response to the vaccine in subjects was similar to a healthy cohort in spite of lower increases in total IgG antibodies. The CD4 and CD8 results observed may support the capacity to mount an effective cellular response in patients on biologics. Larger studies are needed to determine vaccine efficacy in these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding This work was supported by NIGMS award U54GM133807 and by 1U01CA260541-01 to CAS (NCI/NIAID). The Puerto Rico Science, Technology and Research Trust also supported the research reported in this work under agreement number 2020-00272 to CAS and AME. Role of funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies are approved by the Medical Sciences Campus IRB. Volunteers in the control group were participating in the IRB approved clinical protocol Molecular Basis and Epidemiology of Viral infections circulating in Puerto Rico, Pro0004333. Protocol was submitted to, and ethical approval was given by, Advarra IRB on April 21, 2020. That protocol also received ethical approval from the Medical Sciences Campus IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to this work is available upon request}, URL = {https://www.medrxiv.org/content/early/2021/09/15/2021.09.11.21263211}, eprint = {https://www.medrxiv.org/content/early/2021/09/15/2021.09.11.21263211.full.pdf}, journal = {medRxiv} }